AYTU BIOPHARMA, INC Increase (Decrease) in Prepaid Expense and Other Assets
AYTU BIOPHARMA, INC (AYTU) reported Increase (Decrease) in Prepaid Expense and Other Assets of $176.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-09-22
- AYTU BIOPHARMA, INC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$2.85M.
- AYTU BIOPHARMA, INC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.02M, a 22.58% increase year-over-year.
- AYTU BIOPHARMA, INC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $1.48M, a 85.84% increase year-over-year.
- AYTU BIOPHARMA, INC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$484.00K.
- AYTU BIOPHARMA, INC increase (decrease) in prepaid expense and other assets for fiscal 2026 was $176.00K, a 60.98% decline from fiscal 2025.
- AYTU BIOPHARMA, INC increase (decrease) in prepaid expense and other assets for fiscal 2025 was $451.00K.
- AYTU BIOPHARMA, INC increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$329.00K.
- AYTU BIOPHARMA, INC increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$846.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | -$823.00K derived: sum of 2 quarters · filed 2026-09-22 | $660.00K derived: sum of 3 quarters · filed 2026-09-22 | $176.00K 10-K · filed 2026-09-22 | |||
| 2026-03-31 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $3.51M derived: sum of 2 quarters · filed 2026-05-13 | $3.02M 10-Q · filed 2026-05-13 | $1.14M derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-12-31 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $999.00K 10-Q · filed 2026-02-03 | -$881.00K derived: sum of 3 quarters · filed 2026-09-22 | $771.00K derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-09-30 | -$484.00K 10-Q · filed 2025-11-13 | -$2.36M derived: sum of 2 quarters · filed 2026-09-22 | -$712.00K derived: sum of 3 quarters · filed 2026-09-22 | $86.00K derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-06-30 | -$1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | -$228.00K derived: sum of 2 quarters · filed 2026-09-22 | $570.00K derived: sum of 3 quarters · filed 2026-09-22 | $451.00K 10-K · filed 2026-09-22 | |||
| 2025-03-31 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $2.45M derived: sum of 2 quarters · filed 2026-05-13 | $2.33M 10-Q · filed 2026-05-13 | $1.81M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $798.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $679.00K 10-Q · filed 2026-02-03 | $156.00K derived: sum of 3 quarters · filed 2026-02-03 | -$480.00K derived: sum of 4 quarters · filed 2026-02-03 | |||
| 2024-09-30 | -$119.00K 10-Q · filed 2025-11-13 | -$642.00K derived: sum of 2 quarters · filed 2025-11-13 | -$119.00K 10-Q · filed 2024-11-13 | $677.00K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | -$1.16M derived: sum of 2 quarters · filed 2025-09-23 | $796.00K derived: sum of 3 quarters · filed 2025-09-23 | -$329.00K 10-K · filed 2025-09-23 | -$1.53M 10-K · filed 2024-09-26 | ||
| 2024-03-31 | -$636.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $1.32M derived: sum of 2 quarters · filed 2025-05-14 | $194.00K 10-Q · filed 2025-05-14 | -$863.00K 10-Q · filed 2024-05-15 | -$4.25M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $830.00K 10-Q · filed 2025-02-12 | $321.00K 10-Q · filed 2024-02-14 | -$3.62M derived: sum of 3 quarters · filed 2025-02-12 | -$4.62M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-09-30 | -$1.13M 10-Q · filed 2023-11-14 | -$5.57M derived: sum of 2 quarters · filed 2024-09-26 | -$467.00K 10-Q · filed 2024-11-13 | -$3.77M derived: sum of 4 quarters · filed 2024-09-26 | |||
| 2023-06-30 | -$4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | -$5.45M derived: sum of 2 quarters · filed 2024-09-26 | -$2.65M derived: sum of 3 quarters · filed 2024-09-26 | -$846.00K 10-K · filed 2024-09-26 | $914.00K 10-K · filed 2023-10-12 | ||
| 2023-03-31 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $1.80M derived: sum of 2 quarters · filed 2024-05-15 | $3.60M 10-Q · filed 2024-05-15 | $2.78M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $4.61M 10-Q · filed 2024-02-14 | $3.78M derived: sum of 3 quarters · filed 2024-02-14 | $482.00K derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2022-09-30 | $1.80M 10-Q · filed 2023-11-14 | $979.00K derived: sum of 2 quarters · filed 2023-11-14 | -$2.32M derived: sum of 3 quarters · filed 2023-11-14 | -$148.00K derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | -$822.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | -$4.12M derived: sum of 2 quarters · filed 2023-10-12 | -$1.95M derived: sum of 3 quarters · filed 2023-10-12 | -$2.23M 10-K · filed 2023-10-12 | |||
| 2022-03-31 | -$3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | -$1.13M derived: sum of 2 quarters · filed 2023-05-11 | -$1.41M 10-Q · filed 2023-05-11 | $6.11M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $2.17M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | $1.90M 10-Q · filed 2023-02-21 | $9.41M derived: sum of 3 quarters · filed 2023-02-21 | $3.56M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-09-30 | -$279.00K 10-Q/A · filed 2023-02-21 | $7.24M derived: sum of 2 quarters · filed 2023-02-21 | $1.38M derived: sum of 3 quarters · filed 2023-02-21 | $1.25M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-06-30 | $7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $1.66M derived: sum of 2 quarters · filed 2022-09-27 | $1.53M derived: sum of 3 quarters · filed 2022-09-27 | -$157.00K 10-K · filed 2022-09-27 | |||
| 2021-03-31 | -$5.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | -$5.98M derived: sum of 2 quarters · filed 2022-05-16 | -$7.67M 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | -$126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | -$1.82M 10-Q · filed 2022-02-14 | |||||
| 2020-09-30 | -$1.69M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |